On May 7, 2014 Oxford BioTherapeutics reported that it has obtained the exclusive global rights to certain Xenomouse antibodies generated by Amgen and to ImmunoGen’s maytansinoid ADC technology for an undisclosed target (Press release Oxford BioTherapeutics, MAY 7, 2014, View Source [SID:1234500495]). The rights were granted under the existing strategic collaboration between Oxford BioTherapeutics and Amgen. Oxford BioTherapeutics intends to use the antibodies and ADC technology to develop a novel ADC targeting a protein in HER2-negative breast cancer, initially focusing on triple negative breast cancer, and other cancers, where the target is expressed. The target was identified using the Company’s OGAP discovery technology.
This novel antibody-based cancer therapy has completed in vivo proof-of-concept in several solid and liquid tumor models and exploratory toxicology testing, and is currently undergoing preparation for an IND application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!